Research & Development

久久精品视频在线看15色哥哥-最新成人激情网一本道久久久999超强台风利奇马灾情善后 浙江保险业已收报损超20亿


第一六一章 劉徹的疑惑   這些人絕對不是雲瑯能駕馭的了的。久久精品视频在线看15   任安笑道︰“我素來治學于二李,這門學問多偏頗,恐怕與西北理工之術不合!”色哥哥-最新成人激情网   司馬遷哈哈大笑道︰“有如此善心,活該你錦衣玉食啊!”   “能成親就不錯了,再不成親,妞妞就要顯懷了,那時候她就沒活路了。”一本道久久久999   “白登山的勝敗不在匈奴,而在于朝堂之上,如今,我已經做好了萬全的準備,你做好了麼?”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo